Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1607

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1607
---
 Renewal 
    $-  
    $50,570 
  
    Debt Discount Recorded in Connection with Derivative Liabilities 
    $-  
    $650,000 
  
    Stock Issued for Payment of Deferred Compensation 
    $-  
    $520,000 
  
    Stock Issued for Acquisition of Intangibles 
    $-  
    $33,895 

See accompanying notes to these consolidated
financial statements which are an integral part of these consolidated financial statements.

F-7

60 DEGREES PHARMACEUTICALS,
INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. NATURE OF OPERATIONS

60 Degrees Pharmaceuticals, Inc. was incorporated
in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability
company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively
as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that
specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA
approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development
covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i)
new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s
headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.

Initial Public Offering

On July 14, 2023, the Company closed its initial
public offering consisting of 23,585 units at a price of $318.00 per unit for $6,454,325 in net proceeds, after deducting the underwriting
discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted
of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $365.70 per share (a
“Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock